Suven Life Sciences completes enrollment in global Phase 3 masupirdine study
Suven Life Sciences Ltd has completed patient enrollment in its global Phase 3 masupirdine study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.